Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.31 - HK$5.47
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$582.14M
Enterprise ValueHK$547.07M
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
Structural Heart FocusVenus Medtech's concentrated focus on transcatheter aortic valve implantation (TAVI) and related interventional cardiovascular devices aligns with durable secular trends: aging populations and migration to less invasive procedures. This specialization supports differentiated R&D, clinical adoption pathways and long-run procedure-driven demand.
Improving LeverageA materially lower debt-to-equity ratio reduces refinancing and solvency risk, extending runway for clinical trials and commercialization. Improved balance-sheet flexibility helps finance strategic investments or absorb temporary revenue weakness without immediate forced dilution or distress financing.
Solid Gross MarginsSustained gross margins indicate product-level pricing power and favorable manufacturing economics. If the company stabilizes sales and tightens operating expenses, these margins enable faster progress to operating leverage and eventual profitability, supporting long-term unit economics for device adoption.
Bears Say
Sharp Revenue DeclineA ~30% revenue drop in 2025 signals weakening commercial traction and scaling difficulty. Reduced procedure volumes or slower hospital adoption directly shrink the addressable near-term revenue base, making investment payback longer and increasing uncertainty around sustainable market share and future revenue recoveries.
Persistent LossesOngoing operating and net losses indicate an unresolved path to profitability. Persistent negative returns dilute equity over time, limit reinvestment capacity from internal cash flows, and make strategic optionality dependent on external funding or material margin improvement for long-term viability.
Weak Cash GenerationConsistent negative operating and free cash flow with worsening 2025 cash burn increases reliance on external capital. That reliance can dilute shareholders, delay commercialization initiatives, and constrain spending on sales, clinical evidence and regulatory approvals that are critical for durable market penetration.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.31 and its highest was HK$5.47 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$582.14M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.682 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.682.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.682 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.543%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
-21.29%
Trailing 12-Months
Asset Growth
-18.86%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
Broncus Holding Corp.
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---